Overview
VBIO market data
Price History
VBIO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$19.68 Diluted earnings per share over the trailing twelve months.
- Beta
- 3.60 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.25 – $1.21 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1.2 · P/B 1.34 · P/S 2.39.
Company News
Ukraine's Ministry Of Health Accepts Valion Bio's Regulatory Dossier For Entolimod For Formal Review Under Regulatory Equivalence PathwayBenzinga · Jul 22, 2026, 11:47 AM
Valion Bio shares are trading lower. The company announced a clinical development milestone with the finalization of a clinical trial protocol at Sheba Medical Center.Benzinga · Jul 20, 2026, 6:20 PM
Valion Bio To Carry Out Study At Sheba Medical Center To Mull Entolimod In 10 Cancer ParticipantsBenzinga · Jul 20, 2026, 5:35 PM
Valion Bio shares are trading lower. The company announced strategic updates for its Entolimod program, including U.S. government engagement, a 200‑fold manufacturing scale‑up, and oncology expansion plans.Benzinga · Jul 14, 2026, 6:28 PM
8-K filing — Valion Bio, Inc. (VBIO)SEC EDGAR · Jul 14, 2026, 11:45 AM
Valion Bio Announces That The Pentagon's Armed Forces Radiobiology Research Institute And National Institute of Allergy and Infectious Diseases Completed Their Design Of Survival Efficacy Protocol To Evaluate The Company's Entolimod To Treat Gastrointestinal Acute Radiation SyndromeBenzinga · Jun 25, 2026, 11:55 AM
Valion Bio Issues $250K Series Securities Under Its April 29, 2025 Securities Purchase Agreement With Undisclosed InvestorBenzinga · Jun 18, 2026, 1:40 PM
Valion Bio shares are trading lower. The company confirmed the FY27 NDAA report directs defense officials to develop a plan for prioritizing radiation and nuclear countermeasures.Benzinga · Jun 11, 2026, 7:44 PM
Valion Bio Confirms That A House Armed Services Committee Report Directs The Pentagon To Plan For Prioritizing Radiation And Nuclear CountermeasuresBenzinga · Jun 11, 2026, 11:50 AM
Valion Bio Advances U.S. Department Of War And BARDA Engagement On Entolimod Radiation Countermeasure; Highlights Interest In Oral Formulation For Field Deployment And National StockpilesBenzinga · May 19, 2026, 8:45 PM